Insulet Statistics
Total Valuation
Insulet has a market cap or net worth of $23.01 billion. The enterprise value is $22.76 billion.
| Market Cap | 23.01B |
| Enterprise Value | 22.76B |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Insulet has 70.39 million shares outstanding. The number of shares has decreased by -4.15% in one year.
| Current Share Class | 70.39M |
| Shares Outstanding | 70.39M |
| Shares Change (YoY) | -4.15% |
| Shares Change (QoQ) | -4.67% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 101.30% |
| Float | 70.08M |
Valuation Ratios
The trailing PE ratio is 98.36 and the forward PE ratio is 65.35. Insulet's PEG ratio is 2.40.
| PE Ratio | 98.36 |
| Forward PE | 65.35 |
| PS Ratio | 9.48 |
| Forward PS | 7.74 |
| PB Ratio | 15.33 |
| P/TBV Ratio | 17.13 |
| P/FCF Ratio | 55.37 |
| P/OCF Ratio | 43.45 |
| PEG Ratio | 2.40 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.35, with an EV/FCF ratio of 56.20.
| EV / Earnings | 96.40 |
| EV / Sales | 9.65 |
| EV / EBITDA | 47.35 |
| EV / EBIT | 57.78 |
| EV / FCF | 56.20 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.99.
| Current Ratio | 2.26 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.99 |
| Debt / EBITDA | 2.99 |
| Debt / FCF | 3.59 |
| Interest Coverage | 7.91 |
Financial Efficiency
Return on equity (ROE) is 19.18% and return on invested capital (ROIC) is 9.20%.
| Return on Equity (ROE) | 19.18% |
| Return on Assets (ROA) | 7.75% |
| Return on Invested Capital (ROIC) | 9.20% |
| Return on Capital Employed (ROCE) | 16.02% |
| Revenue Per Employee | $605,000 |
| Profits Per Employee | $60,538 |
| Employee Count | 3,900 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Insulet has paid $34.60 million in taxes.
| Income Tax | 34.60M |
| Effective Tax Rate | 12.78% |
Stock Price Statistics
The stock price has increased by +38.15% in the last 52 weeks. The beta is 1.40, so Insulet's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | +38.15% |
| 50-Day Moving Average | 325.96 |
| 200-Day Moving Average | 292.97 |
| Relative Strength Index (RSI) | 56.46 |
| Average Volume (20 Days) | 568,549 |
Short Selling Information
The latest short interest is 1.46 million, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 1.46M |
| Short Previous Month | 1.50M |
| Short % of Shares Out | 2.07% |
| Short % of Float | 2.08% |
| Short Ratio (days to cover) | 2.22 |
Income Statement
In the last 12 months, Insulet had revenue of $2.36 billion and earned $236.10 million in profits. Earnings per share was $3.32.
| Revenue | 2.36B |
| Gross Profit | 1.66B |
| Operating Income | 393.90M |
| Pretax Income | 270.70M |
| Net Income | 236.10M |
| EBITDA | 480.70M |
| EBIT | 393.90M |
| Earnings Per Share (EPS) | $3.32 |
Balance Sheet
The company has $1.12 billion in cash and $1.46 billion in debt, giving a net cash position of -$333.80 million or -$4.74 per share.
| Cash & Cash Equivalents | 1.12B |
| Total Debt | 1.46B |
| Net Cash | -333.80M |
| Net Cash Per Share | -$4.74 |
| Equity (Book Value) | 1.46B |
| Book Value Per Share | 20.78 |
| Working Capital | 1.27B |
Cash Flow
In the last 12 months, operating cash flow was $516.20 million and capital expenditures -$111.20 million, giving a free cash flow of $405.00 million.
| Operating Cash Flow | 516.20M |
| Capital Expenditures | -111.20M |
| Free Cash Flow | 405.00M |
| FCF Per Share | $5.75 |
Margins
Gross margin is 70.18%, with operating and profit margins of 16.69% and 10.01%.
| Gross Margin | 70.18% |
| Operating Margin | 16.69% |
| Pretax Margin | 11.47% |
| Profit Margin | 10.01% |
| EBITDA Margin | 20.37% |
| EBIT Margin | 16.69% |
| FCF Margin | 17.16% |
Dividends & Yields
Insulet does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.15% |
| Shareholder Yield | 4.15% |
| Earnings Yield | 1.05% |
| FCF Yield | 1.81% |
Analyst Forecast
The average price target for Insulet is $337.06, which is 3.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $337.06 |
| Price Target Difference | 3.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 17.70% |
| EPS Growth Forecast (5Y) | 11.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Insulet has an Altman Z-Score of 6.86 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.86 |
| Piotroski F-Score | 7 |